SCHEMBL22246459

SCHEMBL22246459

Cc1cc(-c2cc3ccc(=O)[nH]c3nc2-c2cccc(C#N)c2C)cc(Cl)c1NS(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 9/20 0.46
▸ TDP2 O95551 3/20 0.34
▸ PDE3B Q13370 1/20 0.33
▸ PDE3A Q14432 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ HSP90AB1 P08238 1/20 0.33
▸ NUDT1 P36639 1/20 0.33
▸ CNR1 P21554 2/20 0.31
▸ CNR2 P34972 2/20 0.31
▸ SCN9A Q15858 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ GALR3 O60755 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22246455 0.92 ADORA2A (0.38) ADORA2ATDP2PDE3BPDE3AHSP90AA1
SCHEMBL22250316 0.87 ADORA2A (0.40) ADORA2ATDP2HSP90AA1HSP90AB1NUDT1
SCHEMBL22246470 0.84 ADORA2A (0.67) ADORA2AHSP90AA1HSP90AB1NUDT1CNR1
SCHEMBL22246461 0.83 PDE3B (0.38) ADORA2APDE3BPDE3AHSP90AA1KDM4E
SCHEMBL22246487 0.81 ADORA2A (0.47) ADORA2APDE3BPDE3ACNR1CNR2
SCHEMBL22246417 0.79 ABL1 (0.38) PDE3BPDE3ACNR1SCN9A
SCHEMBL22246481 0.79 ADORA2A (0.49) ADORA2APDE3BPDE3ACNR1CNR2
SCHEMBL22246412 0.79 ADORA2A (0.53) ADORA2APDE3BPDE3ACNR1CNR2
SCHEMBL22246413 0.79 ADORA2A (0.47) ADORA2APDE3BPDE3ACNR1CNR2
SCHEMBL22246317 0.79 ADORA2A (0.47) ADORA2APDE3BPDE3ACNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169648-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2022-06-02 — — US disclosed
US-11254670-B2 1,8-naphthyridinone compounds and uses thereof NUVATION BIO INC. (US) 2022-02-22 — — US disclosed
US-20200231589-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2020-07-23 — — US disclosed
WO-2020150676-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254670-B2 1,8-naphthyridinone compounds and uses thereof NME1, ADORA2A, GPR68 ADORA2A 2/4885TDP2 2360/4885PDE3B 557/4885
US-20200231589-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 ADORA2A 2/4885TDP2 2360/4885PDE3B 557/4885
US-20220169648-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 ADORA2A 2/4885TDP2 2360/4885PDE3B 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback